Small Cell Lung Cancer (SCLC)

Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.

Data presented at WCLC 2026 support the use of B7-H3–directed antibody-drug conjugates and brain MRI surveillance in small cell lung cancer.

The FDA reduced the recommended monitoring time for the first 2 doses of tarlatamab to 6 to 8 hours in extensive-stage small cell lung cancer.

Data from the phase 3 DeLLphi-305 trial also showed meaningful improvements in progression-free survival and responses with durvalumab/tarlatamab in SCLC.

Data from a real-world cohort showed that LEMS was diagnosed more frequently by neurologists than by oncologists.

New CNS metastasis data link gabapentin to fewer brain mets, spotlight trial barriers, and show promise for intrathecal therapy and osimertinib.

Laura Alder, MD, discussed a retrospective analysis evaluating tarlatamab’s efficacy and safety in patients with SCLC and brain metastases excluded from DeLLphi-304.

Phase 1b study data show that izalontamab brengitecan produced a 48.1% objective response rate in previously treated extensive-stage small cell lung cancer.

The approval status of lurbinectedin as first-line care for those with small cell lung cancer will not be affected following results from the LAGOON trial.

In a real-world CASCADE database analysis, prophylactic cranial irradiation was associated with a median overall survival of 29.8 months in limited-stage SCLC.

Based on phase 2 data, adding consolidative thoracic radiation cannot be recommended outside of clinical trials for unselected patients with ES-SCLC.

Exploratory data showed that serplulimab maintenance or continuation beyond initial progression may yield incremental survival benefits in ES-SCLC.

ARTEMIS-008 is the first phase 3 trial to show positive overall survival data for a B7-H3–targeted antibody-drug conjugate in any tumor type.

Investigators observed no new safety signals with lurbinectedin alone or in combination with irinotecan in the phase 3 LAGOON trial.

Data from the phase 3 DeLLphi-304 trial support the European Commission’s approval of tarlatamab in extensive-stage small cell lung cancer.

The ivonescimab-based regimen appeared effective in both platinum-sensitive and platinum-resistant cohorts in a phase 2 study.

SNB-101 monotherapy has previously demonstrated encouraging activity among patients with pretreated small cell lung cancer.

The FDA has assigned a Prescription Drug User Fee Act date of October 10, 2026, for ifinatamab deruxtecan in extensive-stage small cell lung cancer.

Read this discussion to spot LEMS red flags tied to small cell lung cancer, avoid misdiagnosis, and follow antibody/EMG testing and screening steps.

Results from the ARTEMIS-001 trial previously showed that the B7-H3–targeted ADC elicits deep responses in patients with ES-SCLC.

Experts discussed how treatment should be sequenced for patients with small cell lung cancer who have brain metastases, highlighting recent clinical trial advancements and safety considerations.

Patients with SCLC who received ociperlimab and tislelizumab plus cCRT achieved a median PFS of 12.6 months compared with 9.5 months with cCRT alone.

Higher ECOG performance statuses and metastatic burden predicted poorer outcomes with frontline adebrelimab for those with extensive-stage SCLC.

Grade 3 immune-mediated AEs were observed in 11 patients with extensive-stage small cell lung cancer, which included 2 instances of pneumonitis.

In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.